Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Feb 14;2023:1744102. doi: 10.1155/2023/1744102

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 Haoran Li et al.

This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

LINC00578 is upregulated in pancreatic cancer and correlated with clinicopathological factors. (a) Box plot of LINC00578 expression in 34 kinds of cancers from the TCGA (PANCAN, N = 19131, T = 60499) cohort. (b) Box plot of LINC00578 expression in both pancreatic cancer tissues (n = 177) and normal tissues (n = 171) from the TCGA-GTEx cohort. (c) Box plot of LINC00578 expression in pancreatic cancer tissues (n = 50) and adjacent normal tissues (n = 50) from the Su cohort. (d) The expression ratio of LINC00578 between tumors and adjacent normal tissues from the Su cohort. (e) The expression of LINC00578 between T1/T2 and T3/T4 stages from the Su cohort. (f) The expression of LINC00578 between N0 and N1/N2 stages from the Su cohort. (g) The expression of LINC00578 between Grade I and Grade II from the Su cohort. (h) Kaplan–Meier curve showing the correlation of the LINC00578 expression with overall survival (OS) (P = 0.04) in the TCGA cohort. ^∗P < 0.05; ^∗∗P < 0.01; ^∗∗∗P < 0.001; ^∗∗∗∗P < 0.0001. Abbreviations: ACC: adrenocortical carcinoma; ALL: acute lymphoblastic leukemia; BLCA: bladder urothelial carcinoma; CESC: cervical squamous cell carcinoma and endocervical adenocarcinoma; COAD: colon adenocarcinoma; COADREAD: colon adenocarcinoma/rectum adenocarcinoma; CHOL: cholangiocarcinoma; ESCA: esophageal carcinoma; GBM: glioblastoma multiforme; GBMLGG: glioma; HNSC: head and neck squamous cell carcinoma; KICH: kidney chromophobe; KIRC: kidney renal clear cell carcinoma; KIRP: kidney renal papillary cell carcinoma; KIPAN: pankidney cohort (KICH+KIRC+KIRP); LAML: acute myeloid leukemia; LGG: brain lower grade glioma; LIHC: liver hepatocellular carcinoma; LUAD: lung adenocarcinoma; LUSC: lung squamous cell carcinoma; OV: ovarian serous cystadenocarcinoma; PAAD: pancreatic adenocarcinoma; PCPG: pheochromocytoma and paraganglioma; PRAD: prostate adenocarcinoma; READ: rectum adenocarcinoma; STAD: stomach adenocarcinoma; STES: stomach and esophageal carcinoma; SKCM: skin cutaneous melanoma; THCA: thyroid carcinoma; TGCT: testicular germ cell tumors; UCEC: uterine corpus endometrial carcinoma; UCS: uterine carcinosarcoma; WT: high-risk Wilms tumor.